Combination VaccinesModerna reported positive Phase 3 results for both its investigational next-generation COVID-19 vaccine and its combination vaccine targeting both COVID-19 and influenza.
Safety ProfileGBS cases remain higher among the PFE vs GSK vaccine and the lowest among MRNA vaccine. Thus, MRNA bodes well from a safety standpoint despite lower end second season efficacy.
Vaccine ApprovalsModerna recently had its second-ever product approved, as the FDA approved mRESVIA, an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.